北京若生智能科技有限公司
Drug Database
HY

hyaluronidase (Amphadase)

✓ Approved

Amphastar Pharmaceuticals, Inc. · HYAL1

什么是 hyaluronidase？

hyaluronidase 是一种治疗药物，由Amphastar Pharmaceuticals, Inc.研发。该药已获批，用于治疗相关适应症，给药途径：Injectable (Others)、Subcutaneous Injection。

药物档案

商品名Amphadase
公司Amphastar Pharmaceuticals, Inc.
分子靶点HYAL1
给药途径Injectable (Others), Subcutaneous Injection
状态Approved
来源： ClinicalTrials.gov, Amphastar Pharmaceuticals, Inc.

作用机制

分子靶点

hyaluronidase 作用于 1 个分子靶点：

HYAL1hyaluronidase 1 (LUCA1, MPS9)
需要更深入的分析？Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

hyaluronidase 针对 1 个适应症，涉及 1 个治疗领域。

治疗领域疾病/病症分期
Surgical and medical proceduresAdjuvant therapy✓ Approved

相关研究文献

PubMedThe British journal of dermatology2026-09-11

Efficacy and safety of subcutaneous efgartigimod with prednisone in moderate-to-severe pemphigus (ADDRESS): a global, phase III, randomised controlled, double-blind trial.

Joly Pascal P, Murrell Dedee F DF, Aoyama Yumi Y, Caux Frédéric F et al.

Pemphigus vulgaris (PV) and pemphigus foliaceus (PF) are rare, chronic, potentially life-threatening, immunoglobulin (Ig)G-mediated, autoimmune skin and/or mucosal blistering diseases. Efgartigimod, a human IgG1 antibody Fc fragment, blocks the neonatal Fc receptor, decreasing IgG recycling and reducing both healthy and pathogenic IgG autoantibody levels. To investigate the efficacy, safety and impact of subcutaneous efgartigimod PH20 (co-formulated with recombinant human hyaluronidase PH20) in conjunction with prednisone in the treatment of pemphigus. Adult participants with newly diagnosed or relapsing moderate-to-severe pemphigus were recruited in this phase III, prospective, multicentre, randomised, double-blinded, placebo-controlled study (NCT04598451). Participants were randomised (2 : 1) to weekly subcutaneous efgartigimod PH20 or placebo. Subcutaneous efgartigimod PH20 2000 mg was administered on days 1 and 8, followed by 1000 mg weekly until complete remission on minimal prednisone therapy (CRmin) (≤ 10 mg daily). All participants received concomitant prednisone starting at 0.5 mg kg-1 daily. The primary outcome was the proportion of participants with PV who achieved CRmin by week 30, while receiving minimal prednisone, for ≥ 8 weeks. Pharmacodynamics and safety were also assessed. Overall, 222 participants (PV: n = 190; PF: n = 32) were randomised (subcutaneous efgartigimod PH20: n = 147; placebo: n = 75). The proportions of participants with PV achieving CRmin within 30 weeks were comparable between the subcutaneous efgartigimod PH20 and placebo groups, with no statistically significant difference observed [44/124 (35.5%) vs. 20/66 (30.3%); P = 0.60; odds ratio 1.19 (95% confidence interval 0.60-2.41)]. Total prednisone consumption over time was comparable between groups. Subcutaneous efgartigimod PH20 resulted in rapid reductions from baseline in total IgG and anti--desmoglein-1 and anti-desmoglein-3 autoantibody levels, but these did not translate to improvements in Pemphigus Disease Area Index scores. The rates of adverse events (AEs) in the subcutaneous efgartigimod PH20 and placebo groups were 89.1% (n = 131/147) and 76.0% (n = 57/75), respectively; most were mild to moderate [serious AEs: 12.2% (n = 18/147) and 13.3% (n = 10/75), respectively]. No deaths occurred. Subcutaneous efgartigimod PH20 in combination with systemic corticosteroids did not demonstrate clinical benefit over systemic corticosteroids alone in patients with moderate-to-severe pemphigus at 30 weeks, but it was well tolerated in this patient population.

PMID 42723554
阅读全文 →
PubMedChemistry & biodiversity2026-09-10

Comparative Phytochemical and Biological Evaluation of Four Thymus Species From Türkiye for Dermocosmetic Applications.

Özdemir Nath Ebru E, Campos Pierre-Eric PE, Le Cabec Audrey A, Gündoğan Gül İpek Gİ et al.

Species of Thymus have long been used in Anatolia for wound healing and skin disorders. This study characterized metabolites and biological activities of four taxa-Thymus leucostomus (TL), Thymus sipyleus (TS), Thymus brachychilus (TB), and Thymus migricus (TM)-using UHPLC-HRMS/MS-based molecular networking, anti-aging enzyme inhibition assays, and cellular models (L929 fibroblasts, HaCaT keratinocytes, HUVEC endothelial cells). All taxa showed triterpene-rich profiles, though TL was enriched in polymethoxylated flavonoids and TM in diterpenes. Extracts strongly inhibited hyaluronidase, collagenase and elastase, with more modest tyrosinase inhibition; the highest values were recorded for TB (hyaluronidase, 89.64%), TM (elastase, 78.31%), and TL (collagenase, 82.92%; tyrosinase, 39.74%). Biologically, TL demonstrated the broadest cytocompatibility and significantly enhanced wound closure in fibroblast (≈84.7%) and keratinocyte (≈71.3%) models. TL and TS achieved nearly complete endothelial wound closure, suggesting potential pro-regenerative effects. TL showed lower cytotoxicity in HaCaT and HUVEC cells (IC50 ≈ 0.5 mg/mL), whereas TM exhibited stronger cytotoxicity in keratinocytes (IC50 ≈ 0.1025 mg/mL). TM moderately increased intracellular ROS levels in L929 fibroblasts, while TL and TS maintained ROS levels closer to control conditions. Overall, TL and TS displayed more balanced in vitro profiles regarding wound closure, oxidative balance, and enzyme inhibition, whereas TM required more cautious concentration-dependent interpretation.

PMID 42720075
阅读全文 →
PubMedContemporary oncology (Poznan, Poland)2026-09-09

Clinical guidelines for the management of cytostatic extravasation in children.

Sosnowska-Sienkiewicz Patrycja P, Łohynowicz Anna A, Januszkiewicz-Lewandowska Danuta D

Extravasation of cytostatic drugs is a rare but potentially devastating complication of chemotherapy in children, leading to severe pain, tissue necrosis, functional impairment, and cosmetic deformities. Despite its importance, management protocols remain inconsistent. This paper presents structured instructions to support rapid recognition, intervention, and prevention of cytostatic extravasation in paediatric patients, aiming to reduce morbidity and optimise outcomes. The guidance was developed from published recommendations, systematic reviews, and institutional experience, and it provides a stepwise algorithm for immediate management: stopping infusion, retaining intravenous access for aspiration, marking and documenting the affected site, and performing clinical assessment. Specific measures include aspiration techniques for peripheral and central lines, administration of antidotes such as dexrazoxane, dimethyl sulfoxide, or hyaluronidase, and application of cold or warm compresses depending on the cytostatic agent. Preventive strategies emphasise correct vessel selection, careful cannula monitoring, and strict adherence to administration procedures. For advanced necrosis or refractory injury, surgical approaches - such as early wash-out, liposuction, excision with negative- pressure wound therapy, skin grafting, and complex reconstructions - are outlined. The proposed framework integrates available evidence and expert consensus into a practical and user-friendly protocol. Its implementation may facilitate early detection, minimise the risk of severe complications, and promote standardised paediatric oncology care. In conclusion, cytostatic extravasation in children requires prompt, structured, interdisciplinary management. Early use of specific antidotes and supportive measures can prevent irreversible damage, while preventive strategies and vigilant monitoring remain crucial. Surgical interventions should be reserved for severe, non-responsive cases.

PMID 42712872
阅读全文 →
PubMedACS applied materials & interfaces2026-09-08

Rational Design of a Smart Phototheranostic Nanoagent Based on a NIR-II-Conjugated Polymer for Highly Tumor-Specific Multimodal Imaging-Guided Synergistic Therapy.

Ding Guice G, Wang Yilin Y, Huang Yanqin Y, Wang Yan Y et al.

Exploration of precise cancer therapy promotes the development of tumor microenvironment (TME)-responsive imaging-guided phototheranostic nanoagents. Currently, near-infrared-II (NIR-II, 1000-1700 nm) phototheranostic nanoagents are highly desired for deep and high-fidelity imaging. Besides, nontumor-specific imaging and some inherent physiological conditions in TME have severely hindered the enhancement of therapeutic efficacy. Herein, two amphiphilic conjugated polymers (CPs), P1 and P2, were designed with the backbone containing electron-deficient diketopyrrolopyrrole (DPP) as the acceptor (A) and doped electron-rich fluorene as the donor (D). As the doping ratio of fluorene was tuned from 0 to 0.2, P2 was obtained as an "always-on" probe with excellent NIR-II photoacoustic/fluorescence imaging (PAI/FLI) capability as well as photodynamic/photothermal therapy (PDT/PTT) efficacy. Then, a smart phototheranostic nanoagent P2@MnO2@HA-SS-BFVPBT (PMH) based on the combination of "always-on" and "turn-on" probes was rationally designed for dual-FL/PA imaging-guided synergistic PDT/PTT/chemodynamic therapy (CDT). In PMH, the fluorescence of BFVPBT, a conjugated oligomer linked to the side chains of hyaluronic acid (HA) by cystamine containing disulfide (-SS-) bonds, was quenched by MnO2 via an inner filter effect. After the tumor-targeting delivery of PMH via HA, the degradation of HA-SS-BFVPBT and MnO2 was triggered by overexpressed hyaluronidase (HAase), glutathione (GSH), and H2O2 in TME, leading to the "turn-on" BFVPBT fluorescence and the generation of in situ O2 and Mn2+ along with the consumption of GSH, and thereby synergistically enhancing the efficacy of PDT and Fenton-like reaction-mediated CDT by modulating TME. Moreover, the "always-on" NIR-II photoacoustic/fluorescence intensity and the "turn-on" fluorescence intensity at the tumor site can reach up to about seven times the background intensity, achieving effective dynamic monitoring of the nanoagent distribution in vivo. Thus, this smart nanoagent simultaneously combined active tumor targeting and TME response for highly tumor-specific multimodal imaging-guided synergistic PDT/PTT/CDT, providing a simple and universal strategy for enhancing the precision and efficiency of phototheranostics.

PMID 42709578
阅读全文 →
PubMedACS applied bio materials2026-09-07

Hyaluronidase-Responsive Composite Based on a Ligand-Engineered Ag(I) Complex with Enhancement in Released Ag+ for Targeted Antimicrobial Therapy.

Yan Huan H, Han Jing J, Chen Yixuan Y, Yu Zhong Z et al.

The potential clinical application of silver complexes as resistance-evading antibiotic alternatives for antimicrobial therapy is hindered by their unsatisfactory and uncontrolled Ag+ release, which often causes poor antibacterial efficacy or potential cytotoxicity. To address this limitation, we correlate a ligand engineering strategy to released Ag+ and develop a AgC≡CtBu-based complex (1) by facile exclusion of the N-donor bridging ligand. This structural modulation achieves higher intrinsic silver content (56.48%) with a Ag+ release ratio of 51.17%. Consequently, the same mass of 1 exhibits a boosted Ag+ release of 28.90 mg/L, significantly higher than that of 23.50 mg/L for the complex using the N-donor ligand. 1 exhibits stronger antibacterial activity with a far lower MIC value (3.24 × 10-4 mol Ag/L) than that of the above referenced complex (5.54 × 10-4 mol Ag/L) against Pseudomonas aeruginosa and carbapenem-resistant Escherichia coli. The correlation among coordination structure, Ag+ content, Ag+ release ratio, and antimicrobial activity is established using single crystal X-ray diffraction, atomic absorption spectroscopy, and various antimicrobial analyses. The sophistication of the ligand engineering strategy lies in the removal of the N-donor bridging ligand, which reduces the nuclearity of 1 as an Ag9 cluster ribbon with higher silver content, without compromising Ag+ release. Despite its elevated released Ag+, 1 demonstrates good biocompatibility at concentrations up to 64 mg/L. Further decorating 1 with hyaluronic acid (HA) yields a responsive composite 1@HA. HA coating effectively limits premature Ag+ release to 13.54% under physiological conditions and promotes Ag+ release to 47.18% upon 0.1 wt % hyaluronidase (HAase) exposure. Under the simulated infection, 1@HA exhibits HAase-responsive antibacterial behavior with larger inhibition zones and lower MICs than under noninfection conditions. 1@HA at 32 mg/L can achieve complete carbapenem-resistant Escherichia coli and Pseudomonas aeruginosa killing within 2 h. By decorating the Ag(I) complex featuring higher released Ag+ with HAase-responsive coating, this study provides an effective ligand design approach for enhanced and targeted antimicrobial efficacy.

PMID 42703741
阅读全文 →
PubMedACS applied bio materials2026-09-07

An Infection-Responsive KCoF3@Fe-HA Hydrogel for Localized Co/Fe Dual Fenton-like Therapy of MRSA-Infected Wounds.

Liu Yutong Y, Li Zhonghan Z, Li Jinzhan J, Han Weifan W et al.

Methicillin-resistant Staphylococcus aureus (MRSA)-infected wounds remain difficult to treat because bacterial persistence, inflammation, antimicrobial resistance, and poorly controlled local toxicity can jointly impair tissue repair. Herein, we report an infection-responsive KCoF3@Fe-HA hydrogel that integrates potassium cobalt fluoride (KCoF3) with an Fe3+-crosslinked hyaluronic acid (HA) network for localized Co/Fe dual Fenton-like antibacterial therapy. Notably, the use of KCoF3 in antibacterial wound dressing systems has not yet been reported. In this design, KCoF3 serves as a confined Co reservoir, while the Fe-HA network provides catalytic Fe species and a biodegradable hydrogel matrix. The introduction of Co-mediated Fenton-like activity may broaden the effective catalytic pH range and compensate for the limited activity of Fe-based Fenton-like systems under infection-relevant weakly acidic conditions. Meanwhile, the HA network provides infection responsiveness, allowing weak acidity and bacteria-associated hyaluronidase to promote localized network relaxation and degradation. Together with the reservoir-like KCoF3 structure, this design enables sustained Fe/Co release around infected tissues, helping to maintain local antibacterial activity while reducing burst Co exposure and unnecessary metal leakage. KCoF3@Fe-HA showed stronger Fenton-like catalytic activity than single-metal hydrogel systems. The hydrogel exhibited broad-spectrum antibacterial activity against MRSA, Staphylococcus aureus (S. aureus), and Escherichia coli (E. coli) and effectively reduced bacterial burden in an MRSA-infected full-thickness wound model. Wounds treated with KCoF3@Fe-HA closed faster and showed weaker inflammatory signals, greater collagen deposition, and increased angiogenesis. Cytocompatibility, hemolysis, blood analysis, and major-organ histology supported its preliminary biosafety. This work provides a localized Co/Fe Fenton-like dressing strategy for antibiotic-free MRSA-infected wound healing, presenting KCoF3 as a confined Co reservoir integrated with an infection-responsive HA hydrogel network.

PMID 42703069
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多hyaluronidase